CeriBell (NASDAQ:CBLL – Get Free Report) is projected to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $17.55 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
CeriBell Stock Performance
NASDAQ CBLL opened at $24.69 on Friday. CeriBell has a twelve month low of $18.69 and a twelve month high of $32.75. The firm’s fifty day moving average price is $23.53.
Analysts Set New Price Targets
A number of brokerages have recently commented on CBLL. Bank of America initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group lifted their target price on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. TD Cowen raised their price target on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.60.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
- Five stocks we like better than CeriBell
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Compound Interest and Why It Matters When Investing
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
